Lantheus Holdings, Inc.

LNTH Healthcare Drug Manufacturers Specialty & Generic

Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.

Revenue
+1.54%
EPS
−16.4%
Free cash flow
+7.71%
Total debt
+0.52%

Quarter to September 2026, against a year earlier

100.65 0.05 −0.05%
Market cap
$6.6B
P/E
24.3×
Fwd P/E
21.3×
Dividend yield
—
F-score
5/9
Altman Z
4.25
Beneish M
−2.23
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

19.35 18.02 26.35 24.03
P/S ratio
2.91 3.18 4.64 4.16
P/FCF ratio
12.69 12.85 18.40 16.53
P/Operating CF
49.81 39.24 78.40 63.73
P/B ratio
4.12 4.05 5.51 4.95
EV/Sales
3.05 3.22 4.63 4.09
EV/EBITDA
12.20 13.33 18.23 16.53
EV/FCF
13.28 13.04 18.35 16.25
Current Ratio
2.70 2.83 3.06 3.25
Net Debt/EBITDA
2.08 0.68 (0.18) 0.00
Debt/Equity
0.52 0.47 0.44 0.42
Earnings Yield
5.17% 5.55% 3.79% 4.16%
Free Cash Flow Yield
7.88% 7.78% 5.43% 6.05%
Free Cash Flow per Share
1.21 1.96 1.38 1.45
Book value per Share
16.15 18.73 20.13 20.76
Free Cash Flow
81.39 126.90 89.87 94.93
EV/EBIT
15.13 17.17 23.84 21.95
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026